No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia

Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shi Thong Heng, Swaine L. Chen, Joshua G. X. Wong, David C. Lye, Tat Ming Ng
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
R
Q
Acceso en línea:https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ae5796eed3b7401d9a83da28e86e78fd
record_format dspace
spelling oai:doaj.org-article:ae5796eed3b7401d9a83da28e86e78fd2021-12-02T11:41:24ZNo association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia10.1038/s41598-018-31081-62045-2322https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd2018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-31081-6https://doaj.org/toc/2045-2322Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients with ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia treated empirically with piperacillin-tazobactam and carbapenems was performed. Beta-lactamase resistance mutations and VF were identified by whole genome sequencing (WGS). The primary endpoint was 30-day mortality. Multivariate analyses were performed using logistic regression. WGS showed diverse multilocus sequence types (MLST) in 43 K. pneumoniae strains, while ST131 predominated in E. coli strains (57/80). CTX-M was most commonly detected (76/80 [95%] of E. coli; 39/43 [91%] of K pneumoniae.), followed by OXA (53/80 [66%] of E. coli; 34/43 [79%] of K. pneumoniae). A significant correlation was found between the number of genes encoding third-generation cephalosporin-resistant beta-lactamases and 30-day mortality (p = 0.045). The positive association was not significant after controlling for empiric carbapenem, Pitt score 3 and K. pneumoniae (OR 2.43, P = 0.073). None of the VF was associated with 30-day mortality. No association was found between 30-day mortality and any ESBL and AmpC beta-lactamases or VF when piperacillin-tazobactam or carbapenems were given. No significant association between 30-day mortality and active empiric therapy was found.Shi Thong HengSwaine L. ChenJoshua G. X. WongDavid C. LyeTat Ming NgNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Shi Thong Heng
Swaine L. Chen
Joshua G. X. Wong
David C. Lye
Tat Ming Ng
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
description Abstract The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients with ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia treated empirically with piperacillin-tazobactam and carbapenems was performed. Beta-lactamase resistance mutations and VF were identified by whole genome sequencing (WGS). The primary endpoint was 30-day mortality. Multivariate analyses were performed using logistic regression. WGS showed diverse multilocus sequence types (MLST) in 43 K. pneumoniae strains, while ST131 predominated in E. coli strains (57/80). CTX-M was most commonly detected (76/80 [95%] of E. coli; 39/43 [91%] of K pneumoniae.), followed by OXA (53/80 [66%] of E. coli; 34/43 [79%] of K. pneumoniae). A significant correlation was found between the number of genes encoding third-generation cephalosporin-resistant beta-lactamases and 30-day mortality (p = 0.045). The positive association was not significant after controlling for empiric carbapenem, Pitt score 3 and K. pneumoniae (OR 2.43, P = 0.073). None of the VF was associated with 30-day mortality. No association was found between 30-day mortality and any ESBL and AmpC beta-lactamases or VF when piperacillin-tazobactam or carbapenems were given. No significant association between 30-day mortality and active empiric therapy was found.
format article
author Shi Thong Heng
Swaine L. Chen
Joshua G. X. Wong
David C. Lye
Tat Ming Ng
author_facet Shi Thong Heng
Swaine L. Chen
Joshua G. X. Wong
David C. Lye
Tat Ming Ng
author_sort Shi Thong Heng
title No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
title_short No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
title_full No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
title_fullStr No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
title_full_unstemmed No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia
title_sort no association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant escherichia coli and klebsiella pneumoniae bacteremia
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/ae5796eed3b7401d9a83da28e86e78fd
work_keys_str_mv AT shithongheng noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia
AT swainelchen noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia
AT joshuagxwong noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia
AT davidclye noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia
AT tatmingng noassociationbetweenresistancemutationsempiricantibioticandmortalityinceftriaxoneresistantescherichiacoliandklebsiellapneumoniaebacteremia
_version_ 1718395418921926656